Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000361657

Medchemexpress LLC Rabusertib (LY2603618) | 911222-45-2 | 99.98% | 436.30 | 1 ML
SDP

Catalog No. 5000361657
Encompass_Preferred

Rabusertib (LY2603618) is a potent and selective Chk1 inhibitor with an IC50 of 7 nM. It effectively reduces Chk1 autophosphorylation and abrogates the G2/M DNA damage checkpoint in cells treated with DNA damaging agents. Inhibition of Chk1 by Rabusertib leads to impaired DNA synthesis, elevated H2A.X phosphorylation, and premature entry into mitosis.

  • Potent and selective inhibitor of Chk1 (IC50 of 7 nM)
  • Reduces Chk1 autophosphorylation (EC50 of 430 nM)
  • Abrogates G2/M DNA damage checkpoint
  • Impairs DNA synthesis
  • Elevates H2A.X phosphorylation
  • Induces premature entry into mitosis

Catalog No. 50-003-61657 Supplier Medchemexpress LLC Supplier No. HY1472010MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Rabusertib (LY2603618) is a potent and selective Chk1 inhibitor with an IC50 of 7 nM. It effectively reduces Chk1 autophosphorylation and abrogates the G2/M DNA damage checkpoint in cells treated with DNA damaging agents. Inhibition of Chk1 by Rabusertib leads to impaired DNA synthesis, elevated H2A.X phosphorylation, and premature entry into mitosis.

  • Potent and selective inhibitor of Chk1 (IC50 of 7 nM)
  • Reduces Chk1 autophosphorylation (EC50 of 430 nM)
  • Abrogates G2/M DNA damage checkpoint
  • Impairs DNA synthesis
  • Elevates H2A.X phosphorylation
  • Induces premature entry into mitosis

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.